Roche ’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authoritiesBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance ®) and fu...
Source: Roche Investor Update - December 8, 2023 Category: Pharmaceuticals Source Type: news
Adverse Events Up With Immune Checkpoint Blockade Added to Periop Cancer Therapy
WEDNESDAY, Dec. 6, 2023 -- The addition of an immune checkpoint blockade to perioperative cancer therapy is associated with increased incidence of certain adverse events, according to a review published online Nov. 24 in The Lancet Oncology.
Yu... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 6, 2023 Category: Pharmaceuticals Source Type: news
Replimune Skin Cancer Therapy Fails Midstage Study Replimune Skin Cancer Therapy Fails Midstage Study
Replimune Group said on Tuesday its experimental combination therapy to treat a common form of skin cancer failed to significantly remove or reduce cancerous lesions in a midstage study.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 6, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance1,2Data will be shared with health authorities and presented at an upcoming medical meetingBasel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance ®) a...
Source: Roche Media News - December 5, 2023 Category: Pharmaceuticals Source Type: news
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance1,2Data will be shared with health authorities and presented at an upcoming medical meetingBasel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance ®) a...
Source: Roche Investor Update - December 5, 2023 Category: Pharmaceuticals Source Type: news
How the Microbiome Influences the Success of Cancer Therapy How the Microbiome Influences the Success of Cancer Therapy
Microbial diversity affects whether a tumor grows, leads to inflammation, develops immune escape mechanisms, or develops therapeutic resistance, said an internal medicine specialist.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 4, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Lab Notes: University City Science Center selects 7 local firms for Capital Readiness program
This week's Lab Notes has items on a science incubator's latest cohort, a cell therapy company moving ahead with its lead cancer therapy candidate, and a biotech firm dosing its first patient. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 1, 2023 Category: Pharmaceuticals Authors: John George Source Type: news
Avoid Anti-HER2 Cancer Therapies During Pregnancy Avoid Anti-HER2 Cancer Therapies During Pregnancy
Women with HER2-positive breast cancer who receive HER2-targeted therapies during pregnancy face a higher risk for severe adverse outcomes to their fetus or newborn, new research indicates.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 29, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Lifesaving cancer therapy may itself CAUSE cancer, FDA warns
The US Food and Drug Administration on Tuesday said it was investigating reports of 19 cases of new cancer linked to CAR-T therapies, which are given to terminal blood cancer patients. (Source: the Mail online | Health)
Source: the Mail online | Health - November 29, 2023 Category: Consumer Health News Source Type: news
FDA Looking Into CAR T Therapies on Cancer Risk
The U.S. Food and Drug Administration is investigating certain CAR T cancer therapies based on reports that they might cause a type of white blood cell to become cancerous in patients who received the treatment. CAR T cell immunotherapies work by manipulating a patient’s own disease-fighting white… (Source: Reuters: Health)
Source: Reuters: Health - November 29, 2023 Category: Consumer Health News Source Type: news
Bristol Myers Squibb (NYSE:BMY) Falls after FDA Delays Action on Cancer Therapy - TipRanks.com
Pharmaceutical companies Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (TSVT) are down in trading at the time of writing. This comes after announcing that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) will meet to discuss data supporting the…#bristolmyerssquibb #bmy #fda #odac #karmma3 #futureofbmystock #moderatebuy #holds (Source: Reuters: Health)
Source: Reuters: Health - November 21, 2023 Category: Consumer Health News Source Type: news
Roche ’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (C...
Source: Roche Investor Update - November 14, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (C...
Source: Roche Media News - November 14, 2023 Category: Pharmaceuticals Source Type: news
Identifying trajectories and predictors of chemotherapy-induced peripheral neuropathy symptoms, physical functioning, and falls across treatment and recovery in adults treated with neurotoxic chemotherapy: the PATTERN observational study protocol (NCT05790538) - Winters-Stone KM, Krasnow SM, Horak FB, Mancini M, Cameron MH, Dieckmann NF, Stoyles SA, Roeland EJ.
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting side effect of systemic cancer therapy. In many cancer survivors, CIPN persists after treatment ends and is associated with functional impairments, abnormal g... (Source: SafetyLit)
Source: SafetyLit - November 13, 2023 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., Nov. 3, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on November 1, 2023 the Company granted inducement awards to purchase up to 169,600... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 3, 2023 Category: Pharmaceuticals Source Type: news
